Court Report
By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Galderma Laboratories, LP et al. v. Actavis Mid-Atlantic, L.L.C.
4:08-cv-00115; filed February 21, 2008 in the Northern District of Texas
Infringement of U.S. Patent No. 7,316,810 ("Foaming Composition for Washing and Treating Hair and/or Scalp Based on an Active Principle," issued January 8, 2000) following a paragraph IV certification as part of Actavis' filing of an ANDA to manufacture a generic version of Galderma's Clobex® Shampoo (clobetasol propionate shampoo, used to treat psoriasis). View the complaint here.
Sepracor Inc. et al. v. Geopharma, Inc. et al.
3:08-cv-00945; filed February 20, 2008 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 7,214,683 ("Compositions of Descarboethoxyloratadine," issued May 8, 2007) and 7,214,684 ("Methods for the Treatment of Allergic Rhinitis," issued May 8, 2007), licensed to Schering-Plough, following a paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Schering-Plough's Clarinex® (desloratidine, used to treat allergies). View the complaint here.
Novartis Vaccines and Diagnostics, Inc. v. Wyeth et al.
2:08-cv-00067; filed February 15, 2008 in the Eastern District of Texas
Infringement of U.S. Patent Nos. 6,060,447 ("Protein Complexes Having Factor VIII:C Activity and Production Thereof," issued May 9, 2000) and 6,228,620 (same title, issued May 8, 2001) based on Wyeth's manufacture and sale of its ReFacto® (recombinant antihemophilic Factor VIII, used to treat hemophilia). View the complaint here.
Novartis Vaccines and Diagnostics, Inc. et al. v. Bayer Healthcare, LLC et al.
2:08-cv-00068; filed February 15, 2008 in the Eastern District of Texas
Infringement of U.S. Patent No. 7,138,505 ("Factor VIII:C Nucleic Acid Molecules," issued November 21, 2006) based on defendants' manufacture and sale of their Kogenate® (Bayer) and Helixate® (CSL Behring) (recombinant antihemophilic Factor VIII, used to treat hemophilia). View the complaint here.
Comments